๐ฌ IL-26 reprograms cancer cells to evade immunity
Researchers found that interleukin-26, produced by exhausted T cells, can reprogram colorectal cancer cell epigenomes. This discovery was made by a team led by Assistant Professor Takumi Itoh at Juntendo University, Japan. The findings, published on July 17, 2026, detail how IL-26 drives immune escape against anti-PD-1 therapy. IL-26 activates an epigenetic program that attracts immunosuppressive neutrophils, weakening antitumor T-cells. Targeting IL-26 or BRD4 could potentially boost immunotherapy effectiveness in treatment-resistant cancers. ๐ฌ